Robert M. Jones,Daniel J. Buzard,Sangdon Han,Sun Hee Kim,Juerg Lehmann,Dawei Yue,Xiuwen Zhu
申请号：
US14112384
公开号：
US20140066369A1
申请日:
2012.04.18
申请国别(地区):
US
年份:
2014
代理人:
摘要：
The present invention relates to compounds of Formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of for example, a disorder selected from: a GPR119-receptor-related disorder a condition ameliorated by increasing a blood incretin level a condition characterized by low bone mass a neurological disorder a metabolic-related disorder type 2 diabetes obesity and complications related thereto.
